Skip to main content

Table 1 Baseline characteristics of the study population

From: Effects of tourniquet use on clinical outcomes and cement penetration in TKA when tranexamic acid administrated: a randomized controlled trial

Variable

Group A

(Tourniquet group)

(N = 50)

Group B

(Non-tourniquet group)

(N = 50)

Group C

(Tourniquet in cementation group)

(N = 50)

p value*

Demographic characteristics

 Age (yr)

68.44 ± 6.80

68.00 ± 7.11

68.66 ± 7.27

0.89

 Male sex (%)

7 (14%)

8 (16%)

7 (14%)

 Weight (kg)

64.39 ± 8.16

62.66 ± 10.44

63.64 ± 11.27

0.67

 Height (cm)

153.88 ± 21.49

157.06 ± 6.74

156.52 ± 7.08

0.46

 BMI (kg/m2)

26.13 ± 2.63

25.34 ± 3.61

25.88 ± 3.51

0.42

 ASA status I-II/≥III

(No. of patients)

35/15

38/12

36/14

Diagnosis

 Primary OA

50

50

50

Preoperative laboratory values

 Preo. Hemoglobin (g/dl)

134.84 ± 12.25

132.18 ± 15.10

129.50 ± 14.98

0.17

 Preo. Hematocrit (L/L)

0.41 ± 0.04

0.41 ± 0.04

0.40 ± 0.04

0.82

 Preo. CRP (109/L)

3.94 ± 3.13

3.29 ± 2.00

3.79 ± 2.30

0.41

 Preo. ESR (mm/L)

21.88 ± 12.59

24.08 ± 13.21

28.32 ± 16.87

0.08

 Preo. IL-6 (pg/ml)

4.28 ± 2.04

3.40 ± 2.19

3.76 ± 2.27

0.13

 Preo. CK (IU/L)

81.52 ± 29.89

85.02 ± 39.71

74.06 ± 31.36

0.26

Preoperative knee function

 VAS score (points)

7.28 ± 0.97

7.32 ± 0.95

7.16 ± 0.87

0.67

Range of motion

94 ± 16

97 ± 20

95 ± 14

0.67

 HHS score (points)

56.64 ± 4.24

55.10 ± 4.62

56.74 ± 4.04

0.11

  1. Abbreviations: OA, osteoarthritis; CRP, C-reaction protein; ESR, erythrocyte sedimentation rate; IL-6, interleukin-6; CK, creatine kinase; HSS score, hospital of special surgery score
  2. *The p value represents the result of one-way analysis of variance for independent means for continuous variables or the chi-square test for independent proportions that included the three groups